Please login to the form below

Not currently logged in
Email:
Password:

New London head for comms firm JPA

Valerie Carter has experience at Merck & Co
JPA Valerie Carter

JPA Health Communications has named Valerie Carter as head of its new office in London.

Carter, who has been with JPA since 2011, has more than 22 years' experiences in global public affairs, advocacy and media relations, including a long spell at the pharma company Merck & Co.

“I'm grateful for Valerie's leadership and dedication to the agency,” said Carrie Jones, principal and managing director of JPA.

“Her experience serving the European market will help us enhance our global services while building a thriving practice in London.”

Before joining JPA, Carter was vice president of public affairs at Ricochet PR, responsible for managing and directing all public affairs accounts and projects, focusing on supporting healthcare organisations.

Prior to this she spent 15 years at Merck, ultimately leading the company's government affairs communications efforts, with a focus on extensive grassroots legislative action, Political Action Committee programmes and lobbying.

“I am excited about building a team in London that will expand JPA's capabilities, broaden our experiences and bring unparalleled service to our clients in the EU,” she said.

JPA provides health communications for charity, pharmaceutical and medical device clients. The agency is known for its work in influencer relations, a targeted approach to reaching stakeholders who engage others.

14th January 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics